Channels - Venetoclax Plus Blinatumoma as First Line Therapy for Newly Diagnosed Ph-Negative B-Cell Acute Lymphoblastic Leukemia :: FRELIP Discovery

Similar Items: Venetoclax Plus Blinatumoma as First Line Therapy for Newly Diagnosed Ph-Negative B-Cell Acute Lymphoblastic Leukemia

Quick Look
Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment‐Naive Chronic Lymphocytic Leukemia: A Real‐World Propensity Score‐Matched Study
Quick Look
Acute lymphoblastic leukemia in adolescents and young adults – from genomics to the clinics
Quick Look
Challenges faced in the treatment of acute lymphoblastic leukemia in adolescents and young adults
Quick Look
Thyroid profile in acute lymphoblastic leukemia: prognostic role of thyrotropin-releasing hormone
Quick Look
Venetoclax Plus Hypomethylating Agents for Treatment-Naïve Myelodysplastic Syndromes with Increased Blasts: A Prospective Multicenter Cohort Study
Quick Look
Association of Variants in Candidate Pharmacogenes with Response to Mercaptopurine and Methotrexate in Pediatric Acute Lymphoblastic Leukemia: A Single-Center Experience from Croatia
Quick Look
Poor Outcome of Pediatric Patients with Acute Lymphoblastic Leukemia Harboring Low P16 Deletion Ratio: A Post-Hoc Analysis from a Prospective Cohort
Quick Look
TNFAIP3 Reprograms T Cell Exhaustion and Restores Anti-Leukemia Immunity in Acute Myeloid Leukemia
Quick Look
Prognostic Impact of European LeukemiaNet Genetic Risk Stratification System in Adult Patients With Acute Myeloid Leukemia
Quick Look
Aging Is a Key Driver for Adult Acute Myeloid Leukemia
Quick Look
Mutant NPM1 in Acute Myeloid Leukemia Initiation and Maintenance
Quick Look
Clinical implications of variant allele frequencies of genes in patients with acute myeloid leukemia
Quick Look
Construction and Validation of an N7-Methylguanosine–Related Prognostic Model for Acute Myeloid Leukemia
Quick Look
Early assessment of endocan level as a predictor of remission status in acute leukemia patients
Quick Look
Phase II Trial of an Orelabrutinib-Based Combination Therapy in Newly Diagnosed Primary Central Nervous System Lymphoma
Quick Look
Gain and Loss of Mutations in Patients with Acute Myeloid Leukemia: A Noninterventional Cohort Study (CLEVO)
Quick Look
Exploring the Bone Marrow Microenvironment as a Therapeutic Barrier and Targetable Source of Crosstalk in Acute Myeloid Leukemia
Quick Look
Descriptive Epidemiology and Prognosis of Pediatric Acute Leukemia in the Afro‐Descendant Population of the French West Indies and French Guiana
Quick Look
Study on the Role of Neutrophil Extracellular Traps-Based Risk Model and Discriminative Gene LTF in the Prognosis of Acute Myeloid Leukemia and the Regulation of Immune Microenvironment
Quick Look
Health Disparities in Acute Myeloid Leukemia Patients Undergoing Treatment with Tyrosine Kinase Inhibitor (TKI) Therapy Targeting FLT3, IDH1, or IDH2
Quick Look
First-Line Tislelizumab Plus Chemotherapy for Advanced or Metastatic Squamous Non-Small Cell Lung Cancer: 4-Year Long-Term Follow-Up from RATIONALE-307
Quick Look
A Comprehensive Review of the Role of Zanubrutinib for Patients with Chronic Lymphocytic Leukemia
Quick Look
Bayesian Evaluation of Treatment Effect of Avelumab Plus Axitinib for Advanced Renal Cell Carcinoma
Quick Look
Crosstalk Between FOXN3 and E2F5 Reveals a Novel Tumor Suppressive Pathway in Acute Myeloid Leukemia via MAPK Signaling: Implications for Potential Future Targeted Therapy